{
  "id": "breast-cancer-cdk46-main",
  "display_name": "ER+/HER2- MBC (Main)",
  "cohort": "ER+/HER2- Metastatic Breast Cancer, All Patients, Q1 2023",
  "insight_type": "Treatment Patterns by Regimen",
  "summary": "Standard of care abemaciclib CDK4/6 utilization is at 80% for eligible patients, aligning with NCCN guidelines.",
  "recommendation": "Continue to maintain high standard of care utilization, particularly focusing on maintaining guideline adherence.",
  "financial_impact": 0,
  "financial_impact_description": "Current practice is aligned with best practices.",
  "peer_financial_impact": 0,
  "peer_financial_impact_description": "Your organization is performing well compared to peers.",
  "action_steps": [
    "Continue to monitor CDK4/6 inhibitor utilization",
    "No immediate action required"
  ],
  "peer_action_steps": [
    "Continue current practices",
    "Consider sharing best practices with underperforming organizations"
  ],
  "chart_data": {
    "categories": ["Abemaciclib", "Palbociclib", "Ribociclib", "Everolimus", "Other"],
    "values": [80, 10, 5, 3, 2],
    "peer_values": [65, 20, 8, 5, 2],
    "target_values": [85, 10, 5, 0, 0]
  },
  "drilldowns": [
    {
      "label": "View by Site",
      "description": "Compare regimen utilization by site",
      "jsonFile": "breast-cancer-cdk46-by-site.json"
    },
    {
      "label": "View by Payer",
      "description": "Compare regimen utilization by payer type",
      "jsonFile": "breast-cancer-cdk46-by-payer.json"
    },
    {
      "label": "View by Regimen",
      "description": "Compare regimen utilization in detail",
      "jsonFile": "breast-cancer-cdk46-by-regimen.json"
    }
  ]
} 